TNFRSF9 and experimental autoimmune encephalomyelitis: Moreover, agonistic anti-4-1BB mAbs have been shown to abrogate T cell-dependent antibody responses in vivo (Mittler et al., 1999) and to ameliorate experimental autoimmune encephalomyelitis by skewing the balance against TH17 differentiation in favor of TREG differentiation (Kim et al., 2011).